|
COG5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
8.59380000051146E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.512300E-02 |
| Stage1-vs-Stage3 |
1.810980E-01 |
| Stage1-vs-Stage4 |
2.938200E-02 |
| Stage2-vs-Stage3 |
1.149800E-02 |
| Stage2-vs-Stage4 |
2.957100E-03 |
| Stage3-vs-Stage4 |
3.000800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.03850000002737E-08 |
| Normal-vs-Asian |
1.69553260320754E-12 |
| Caucasian-vs-AfricanAmerican |
2.818400E-01 |
| Caucasian-vs-Asian |
9.968000E-01 |
| AfricanAmerican-vs-Asian |
3.183800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.065600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62825308791525E-12 |
| Normal-vs-Age(81-100Yrs) |
1.181090E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.370600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.235600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.965200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.583400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.904600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.551000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.772100E-04 |
| Classical-VS-Follicular |
6.178600E-04 |
| Classical-VS-Other |
2.240000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
1.62500000011612E-07 |
| Tall-VS-Other |
9.381800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.119600E-03 |
| Follicular-VS-Normal |
3.14460000039318E-07 |
| Other-VS-Normal |
2.37589999996235E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
6.259000E-03 |
|
|
